September 20, 2021
FDA committee votes against COVID-19 vaccine boosters for general population
Editor's Note
The Food and Drug Administration’s (FDA’s) Vaccines and Related Biological Products Advisory Committee on September 17 voted that there was not enough safety and effectiveness data to approve a third Pfizer COVID-19 vaccine dose for those 16 years and older.
The committee did vote to recommend approval of a booster dose for people 65 years and older and those at high risk of severe COVID-19.
The committee also recommended approval of a booster for those with occupational risks, such as healthcare workers and teachers.
Free Daily News
- UCSF surgeons spotlight innovation, perioperative research at national surgical conference
- FDA recalls affect surgical staplers, OR procedure kits, ultrasound systems used in hospitals
- C-sections linked to longer recovery, higher pain, sleep problems for new mothers
- AI model grades nursing procedures with near-human precision
- Study: Hospitals can safely cut low-value preop tests before routine surgeries
- New studies highlight opportunities to improve pediatric anesthesia safety, comfort
- Social and behavioral factors emerging as key predictors of recovery quality after surgery
- Hospitals being squeezed: Anesthesia workforce gaps, payer cuts threaten surgery access
- CDC layoffs cripple national injury and overdose tracking, leaving prevention efforts in doubt
- The Joint Commission makes nurse staffing a national performance goal for 2026
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement